PLK1 and glioblastoma: Furthermore, a novel LNPs CRISPR-Cas9 formulation (sgPLK1-cLNPs) had permitted a safe and effective (~70%) gene editing in vivo of aggressive orthotropic glioblastoma cells by targeting their PLK1 (polo-like kinase 1) gene (24).